Sandra Karanović

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid

Bojan Jelaković, Sandra Karanović, Ivana Vuković Lela et al. · Kidney International · 2011 · 213 citations · Full text

Pharmacy, Molecular Biology, Toxicology +11

Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid

Bojan Jelaković, Xavier Castells, Karla Tomić et al. · International Journal of Cancer · 2014 · 48 citations · Full text

Medicine, Genetics, Oncology +17

Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid

Xavier Castells, Sandra Karanović, Maude Ardin et al. · Cancer Epidemiology Biomarkers & Prevention · 2015 · 24 citations · Full text

Medicine, Molecular Biology, Oncology +17

The acute hypoxic ventilatory response under halothane, isoflurane, and sevoflurane anaesthesia in rats*

Nenad Karanović, Renata Pecotić, Maja Valić et al. · Anaesthesia · 2009 · 20 citations

Medicine, Anesthesiology, Pharmacology +14